A Cost-Effectiveness Analysis of Fingolimod Versus Dimethyl Fumarate As A Second-Line Disease Modifying Treatment In Patients With Highly Active Relapsing-Remitting Multiple Sclerosis.
Raikou M, Kalogeropoulou M, Rombopoulos G
Value Health. 2015 Nov; 18(7):A758. Epub 2015 Oct 20. PMID: 26534245.Abstract